Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 2,103 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable saline Clear all

Conditions: Drug Dependence
Interventions: Cycloserine, Diltiazem, Gabapentin, Isradipine, Naloxone, Nifedipine, Placebo, Saline, Verapamil; Drug · Device
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Traumatic Brain Injury
Interventions: TT301, Placebo; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Respiratory Syncytial Virus
Interventions: mRNA-1345, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 349 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 47
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more

Conditions: Osteoarthritis
Interventions: Monovisc®, Saline; Device · Other
Lead sponsor: Anika Therapeutics, Inc.; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 30
States / cities: Hoover, Alabama • Mesa, Arizona • Phoenix, Arizona + 27 more

Conditions: Dengue
Interventions: YF-17D, TDV, Placebo; Biological · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 11
States / cities: Mobile, Alabama • Pomona, California • Meridian, Idaho + 8 more

Conditions: Degenerative Disc Disease, Low Back Pain, Disc Degeneration
Interventions: VIA Disc NP; Other
Lead sponsor: VIVEX Biologics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Larkspur, California • Santa Monica, California • Walnut Creek, California + 3 more

Conditions: Plantar Fascitis
Interventions: Xeomin; Drug
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hyperbilirubinemia, Neonatal
Interventions: Stannsoporfin, Placebo, PhotoTherapy (as needed); Drug · Other
Lead sponsor: InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company; Industry
Eligibility: 1 Minute to 48 Hours
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 9
States / cities: Colton, California • San Diego, California • Honolulu, Hawaii + 5 more

Conditions: Respiratory Syncytial Virus
Interventions: Placebo, mRNA-1345; Drug
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 36,814 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 133
States / cities: Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 114 more

Conditions: Smallpox
Interventions: Live vaccinia virus vaccine, MVA Smallpox Vaccine, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 38 Years
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 7
States / cities: Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 4 more

Conditions: Urinary Catheter Blockage and Encrustation
Interventions: NVC-422, 0.2%, Sterile normal saline, 0.9%; Drug
Lead sponsor: NovaBay Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 8
States / cities: Downey, California • Naples, Florida • West Orange, New Jersey + 5 more

Conditions: Systemic Lupus Erythematosus
Interventions: Triptorelin Pamoate, placebo; Drug · Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 9 Years to 21 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 9
States / cities: Los Angeles, California • Chicago, Illinois • Hackensack, New Jersey + 6 more

Conditions: Crohn Disease
Interventions: certolizumab pegol (CDP870, CZP), Placebo; Biological · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 24
States / cities: Pell City, Alabama • Colorado Springs, Colorado • Lakewood, Colorado + 21 more

Conditions: Influenza
Interventions: VXA-A1.1, Fluzone®, Placebo Tablets, Saline Solution for Placebo IM Injection; Biological · Other
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Costa Mesa, California

Conditions: Non-Proliferative Diabetic Retinopathy
Interventions: Faricimab; Drug
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 16
States / cities: Bakersfield, California • Modesto, California • Orlando, Florida + 13 more

Conditions: Degenerative Disc Disease
Interventions: IDCT, Saline Solution, Sodium Hyaluronate; Biological · Drug
Lead sponsor: DiscGenics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more

Conditions: ST-Elevation Myocardial Infarction
Interventions: eptifibatide, normal saline; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: Ormond Beach, Florida • Rochester, Michigan • Mansfield, Ohio

Conditions: Graft vs Host Disease
Interventions: Begelomab, Conventional Second-line Treatment; Biological
Lead sponsor: Adienne SA; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Duarte, California • Westwood, Kansas • Boston, Massachusetts + 7 more

Conditions: Prostate Cancer, Lower Urinary Tract Symptoms, Radioactive Seed Implantation
Interventions: Botox injection, Saline injection; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Depemokimab, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 961 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 56
States / cities: Sheffield, Alabama • Aurora, Colorado • Brooksville, Florida + 48 more

Conditions: Post Operative Pain
Interventions: Liposomal bupivacaine, 0.5% bupivacaine with 1:100,000 epinephrine; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 14 Years and older
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Glomerular Filtration Rate, Acute Kidney Injury
Interventions: MP-3180, Iohexol comparator; Drug · Other
Lead sponsor: MediBeacon; Industry
Eligibility: 22 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: VRC-HIVADV014-00-VP, VRC-HIVDNA009-00-VP, FFB, PBS; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • New York, New York + 3 more

Conditions: COVID-19
Interventions: Dupilumab, Placebo; Biological · Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Charlottesville, Virginia

Search by objective public record fields.

Drug Discrimination in Methadone-Maintained Humans Study 1

Effects of TT301 on Cytokine Levels Post Endotoxin Challenge

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

Safety and Effectiveness of Monovisc® Injection for Osteoarthritis of the Knee

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

VIA Disc NP Pilot for Patients With Symptomatic Degenerated Discs

Treatment of Plantar Fasciitis With Xeomin

A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia

A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

MVA Post-Event: Administration Timing and Boost Study

Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation

Triptorelin for Ovary Protection in Childhood Onset Lupus

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine

Safety and Efficacy of Faricimab in Patients With NPDR

Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration

A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks

Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD

Botulinum Toxin Injection With Prostate Brachytherapy

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

Double-Blinded Randomized Controlled Study Investigating the Efficacy of Exparel (Liposomal Bupivacaine) for Postoperative Pain Relief in Mandibular Third Molar Extractions

Pharmacokinetics of MP-3180 in Healthy Volunteers

Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults

Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients